Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.

Abstract excerpt

Directly inhibiting oncogenic RAS proteins has proven to be an arduous task, as after more than thirty years of intensive investigation, no clinically relevant therapies exist. Recently, two classes of selective small molecule inhibitors that target a cysteine-containing RAS mutant have been developed, representing the first directed approaches to specifically inhibit an oncogenic KRAS mutant. In this...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Allosteric Regulation
• Share to Antineoplastic Agents
• Share to Cysteine